Evidence map›Paper›PMID 32226638›Full record

ArticleJournal of analytical science and technology2015

Nils Rutschke, Jan Zimmermann, Ronny Möller, Gerd Klöck, Mathias Winterhalter, Annika Leune

Open access · diamondAbstract read
In one paragraph

Article in Journal of analytical science and technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Aptamer Applications in Emerging Viral Diseases.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nils Rutschkealtona Diagnostics GmbH, Moerkenstr. 12, 22767 Hamburg, Germany.
Jan Zimmermannaltona Diagnostics GmbH, Moerkenstr. 12, 22767 Hamburg, Germany.
Ronny Mölleraltona Diagnostics GmbH, Moerkenstr. 12, 22767 Hamburg, Germany.
Gerd Klöck2Institute of Environmental Biology and Biotechnology, University of Applied Sciences Bremen, Am Neustadtswall 30, 28199 Bremen, Germany.
Mathias Winterhalter3School of Engineering and Science, Jacobs University, Campus Ring 1, 28759 Bremen, Germany.
Annika Leunealtona Diagnostics GmbH, Moerkenstr. 12, 22767 Hamburg, Germany.
Asklepios Klinik Altona · DEConstructor University · DEHochschule Bremen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReverse transcriptase is an indispensable enzyme for real-time reverse transcriptase (RT)-PCR, a standard method in molecular diagnostics for detection and quantification of defined RNA molecules. The prevention of non-specific products due to elongation of misprimed oligonucleotides by the enzyme at temperatures beneath the specific annealing temperature is one of the biggest challenges in real-time RT-PCR.In the present study, an aptamer directed against the reverse transcriptase was analyzed for its potential to attain a temperature-dependent reverse transcriptase ("hot start" RT).

findingsThe hot start effect was investigated in a one-step real-time RT-PCR assay for the detection of Middle East respiratory syndrome coronavirus (MERS-CoV). Results with aptamer revealed a reduced RT activity at low temperatures while achieving full activity at the specific annealing temperature of 55 °C. Sensitivity (limit of detection (LoD) 95 %) of the MERS-CoV assay was increased by about two times in the presence of aptamer.

conclusionsThe study demonstrates the potential of aptamer-dependent hot start RT for the improvement of diagnostic real-time RT-PCR assays.

Indexed as

Hot startMERS-CoVReal-time RT-PCRReverse transcriptase

Identifiers

PMID32226638
PMCPMC7099353
OpenAlexW1603081158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.